⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7528418 | 0.87 | CYP2D6 (0.47) | — | |
| Acetic Acid SCHEMBL3228026 | 0.78 | FFAR3 (0.50) | — | |
| SCHEMBL26082920 | 0.77 | CYP2D6 (0.71) | — | |
| SCHEMBL307236 | 0.77 | — | — | |
| SCHEMBL11173695 | 0.75 | ALDH1A1 (0.39) | — | |
| SCHEMBL18101859 | 0.74 | CYP2D6 (0.36) | — | |
| SCHEMBL17340316 | 0.74 | — | — | |
| SCHEMBL16404028 | 0.74 | — | — | |
| SCHEMBL12646514 | 0.74 | CYP2D6 (0.36) | — | |
| SCHEMBL10520523 | 0.74 | CES2 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-1101397-A | — | — | None | — | — | JP | disclosed |
| US-20160200795-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | NOVO NORDISK A/S (DK) | 2016-07-14 | — | — | US | disclosed |
| US-20160193353-A1 | FACTOR VIII: REMODELING AND GLYCOCONJUGATION OF FACTOR VIII | NOVO NORDISK A/S (DK) | 2016-07-07 | — | — | US | disclosed |
| US-20160158319-A1 | REMODELING AND GLYCOPEGYLATION OF FIBROBLAST GROWTH FACTOR (FGF) | NOVO NORDISK A/S (DK) | 2016-06-09 | — | — | US | disclosed |
| US-9200049-B2 | Remodeling and glycopegylation of fibroblast growth factor (FGF) | NOVO NORDISK A/S (DK) | 2015-12-01 | — | — | US | disclosed |
| US-9187532-B2 | Glycosylation of peptides via O-linked glycosylation sequences | NOVO NORDISK A/S (DK) | 2015-11-17 | — | — | US | disclosed |
| US-20150274847-A1 | ANTIBODY TOXIN CONJUGATES | NOVO NORDISK AS (DK) | 2015-10-01 | — | — | US | disclosed |
| US-9050304-B2 | Methods of treatment using glycopegylated G-CSF | RATIOPHARM GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-20150111245-A1 | GLYCOPEGYLATED FOLLICLE STIMULATING HORMONE | NOVO NORDISK AS (DK) | 2015-04-23 | — | — | US | disclosed |
| US-9005625-B2 | Antibody toxin conjugates | NOVO NORDISK A/S (DK) | 2015-04-14 | — | — | US | disclosed |
| US-8791066-B2 | Branched PEG remodeling and glycosylation of glucagon-like peptide-1 [GLP-1] | NOVO NORDISK A/S (DK) | 2014-07-29 | — | — | US | disclosed |
| US-8791070-B2 | Glycopegylated factor IX | NOVO NORDISK A/S (DK) | 2014-07-29 | — | — | US | disclosed |
| US-20140170728-A1 | Factor IX: Remodeling and Glycoconjugation of Factor IX | NOVO NORDISK A/S (DK) | 2014-06-19 | — | — | US | disclosed |
| US-20140154230-A1 | Glycopegylated Factor IX | NOVO NORDISK A/S (DK) | 2014-06-05 | — | — | US | disclosed |
| US-20140112903-A1 | Glycopegylated Factor IX | NOVO NORDISK A/S (DK) | 2014-04-24 | — | — | US | disclosed |
| US-8404809-B2 | Glycopegylated factor IX | NOVO NORDISK A/S (DK) | 2013-03-26 | — | — | US | disclosed |
| US-8349308-B2 | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof | MERSANA THERAPEUTICS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8076292-B2 | Factor VIII: remodeling and glycoconjugation of factor VIII | NOVO NORDISK A/S (DK) | 2011-12-13 | — | — | US | disclosed |
| US-20110243880-A1 | MODIFIED POLYMERS FOR DELIVERY OF POLYNUCLEOTIDES, METHOD OF MANUFACTURE, AND METHODS OF USE THEREOF | MERSANA THERAPEUTICS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| JP-H01101397-A | PERFUME COMPOSITION | OGAWA KORYO KK | 1989-04-19 | — | — | JP | disclosed |